Idiopathic Recurrent Acute Pancreatitis (IRAP) (IRAP)
This study has been completed.
Information provided by (Responsible Party):
Nalini Guda, MD, Aurora Health Care
First received: May 28, 2010
Last updated: June 24, 2014
Last verified: June 2014
The purpose of this study is to collect standardized data on the diagnosis and management of idiopathic (unknown cause) recurrent acute pancreatitis. The intent is to collect data for at least five years to obtain information regarding long-term outcomes and obtain comparative effectiveness data.
||Observational Model: Cohort
Time Perspective: Prospective
||The IRAP Registry is a Multi-center Prospective, Collaborative Database Designed to Create a National Registry That Collects Information Concerning Episodes of Idiopathic Recurrent Acute Pancreatitis From Major 'Pancreas' Centers. Intent is to do a Comparative Effectiveness Study of Interventions.
Primary Outcome Measures:
- IDIOPATHIC RECURRENT ACUTE PANCREATITIS (IRAP) [ Time Frame: The goal is to recruit 1000 subjects in 5 years. ] [ Designated as safety issue: No ]
Expect 750 to be treated with ERCP Expect 250 to be treated with conservative treatment. Therefore, the smaller group was used for the sample size analysis.
Smallest difference in QOL for treatment is expected to be 10-20%. For smaller of two treatment groups (N=250), no effect would be 0 got better and 250 did not. If 10% of the subjects improved, 25 would get better and 225 would not. Result: Chi-square analysis yielded a highly significantly difference as follows. Chi-square= 24.253 with 1 degrees of freedom. (P = <0.001). Yates correction for continuity was used in calculating this test.An alternate analysis is that for no effect, 125 subjects would get better and 125 patients would not (random effects model).
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||December 2013 (Final data collection date for primary outcome measure)
Pancreatitis, acute, recurrent
Patients with acute recurrent pancreatitis where the cause is unknown
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Subjects with recurrent pancreatitis presenting to major centers for pancreatic disorders
- 18 years or older
- Able to provide consent
- More than one documented episode of pancreatitis (>3 fold elevation of amylase and or lipase with abdominal pain or with body imaging consistent with pancreatitis: need two of the three)
- Subjects with abdominal pain and enzyme elevation which is <3 fold above normal or absence of imaging findings: these subjects who are undergoing endoscopic interventions but do not fit the "classic criteria" for pancreatitis will be included but the analysis of data of these subjects would be done separately.
Note: subjects with a diagnosis of pancreas divisum and or Sphincter of Oddi dysfunction diagnosed prior to or after entry into the study will be included in the study but their data will be analyzed separately because of the controversy regarding the association of these entities with pancreatitis.
- Unable to give informed consent.
- Definite evidence of biliary or alcoholic pancreatitis.
- Clear evidence of hypertriglyceridemia-induced pancreatitis (triglycerides >1,000 mg/dl).
- Post-ERCP pancreatitis, drug-induced pancreatitis, or any identifiable cause for pancreatitis.
- History of pancreatic surgery.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01133535
|Aurora St. Lukes Medical Center of Aurora Health Care
|Milwaukee, Wisconsin, United States, 53215 |
Aurora Health Care
||Nalini M Guda, MD
||Aurora Health Care
||Nalini Guda, MD, Research Regulatory Specialist, Aurora Health Care
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 28, 2010
||June 24, 2014
||United States: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 26, 2016
Digestive System Diseases